Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833773 | 0.92 | NPY1R (0.37) | JAK2JAK1TYK2JAK3SLC6A4 | |
| SCHEMBL6838737 | 0.92 | JAK2 (0.32) | JAK2JAK1TYK2JAK3NPY1R | |
| SCHEMBL6840099 | 0.89 | NPY1R (0.37) | JAK2JAK1TYK2JAK3SLC6A4 | |
| SCHEMBL6840144 | 0.87 | SLC6A2 (0.37) | SLC6A4 | |
| SCHEMBL6838675 | 0.86 | SLC6A2 (0.36) | SLC6A4 | |
| SCHEMBL6838596 | 0.85 | CCR3 (0.34) | CCR3SLC6A4NPY1R | |
| SCHEMBL6833986 | 0.84 | AVPR2 (0.35) | CCR3NPY1R | |
| SCHEMBL6838718 | 0.84 | CCR3 (0.33) | CCR3NPY1R | |
| SCHEMBL6838635 | 0.82 | NPY1R (0.37) | JAK2JAK1TYK2JAK3SLC6A4 | |
| SCHEMBL6840136 | 0.81 | CCR3 (0.33) | CCR3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | CCR3 66/4885JAK2 30/4885JAK1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.